[Treatment of mucositis pain: News and prospects].
Traitement des douleurs de mucite : actualités et perspectives.
Analgesia, Patient-Controlled
Analgesics
/ therapeutic use
Analgesics, Opioid
/ therapeutic use
Anti-Inflammatory Agents
/ therapeutic use
Humans
Laser Therapy
Molecular Targeted Therapy
Morphine
/ therapeutic use
Mouth Diseases
/ complications
Mucositis
/ complications
Neoplasms
/ therapy
Pain
/ etiology
Pain Management
/ methods
Pain Measurement
/ methods
Practice Guidelines as Topic
Analgesics
Douleur
Laser beam therapy
Laserthérapie
Mucite
Mucositis
Opioids
Opioïdes
Pain
Traitement antalgique
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
15
01
2019
revised:
15
03
2019
accepted:
22
03
2019
pubmed:
11
6
2019
medline:
19
9
2019
entrez:
11
6
2019
Statut:
ppublish
Résumé
Mucositis, an acute inflammation of the digestive mucosa, is one of the main toxicities secondary to oncological treatments. Among its consequences, mucositis-related pain is an important complication due to its intensity and repercussion, especially on quality of life. Treatment of pain plays a central role in management of mucositis. It must be multimodal, combining local and general opioid or non-opioid treatments, adapted to pain intensity and based on international recommendations updated in 2014. A systemic analgesic treatment with morphine with a patient-controlled analgesia device is often necessary in severe mucositis. In case of insufficient analgesia, use of co-analgesics (paracetamol, ketamine, anticonvulsants, and antidepressants) can improve analgesic control and reduce morphine doses. Non-drug strategies (distraction, relaxation, hypnosis) and preventive measures must be a major concern. Among them, laser therapy using a low power athermal laser beam, is a promising therapeutic strategy whose effectiveness is based on its analgesic, anti-inflammatory, and healing properties. Despite many available studies, there is a limited number of clinically effective therapies. New therapeutic agents for the prevention and treatment of mucositis and its pain, based on the biological phenomena involved, must be further developed to improve the efficacy of analgesia.
Identifiants
pubmed: 31178070
pii: S0007-4551(19)30198-5
doi: 10.1016/j.bulcan.2019.03.022
pii:
doi:
Substances chimiques
Analgesics
0
Analgesics, Opioid
0
Anti-Inflammatory Agents
0
Morphine
76I7G6D29C
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
776-783Informations de copyright
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.